T-Cell Engager Therapeutics Summit on June 24-26, 2025 in Boston, United States

The T-cell engager (TCE) field has seen unprecedented growth, with eight approvals in the past two years—most recently tarlatamab—reinforcing its potential as a dominant force in immuno-oncology. Expanding applications in autoimmune diseases and a surge in business development, including Merck and Co.’s acquisition of Harpoon Therapeutics and GSK’s $550M agreement with Chimagen, highlight the industry’s commitment to advancing this modality.

The 7th T-Cell Engager Therapeutics Summit remains the only event exclusively focused on translating TCEs and immune cell engagers from discovery to the clinic and regulatory approval. This year’s program will showcase innovations to improve efficacy and safety in solid tumors while exploring new opportunities in autoimmune indications.

Despite recent successes, challenges persist—identifying novel tumor targets, enhancing durability, reducing on-target, off-tumor toxicity, and optimizing dosing for first-in-human studies. This summit will provide the critical insights needed to overcome these hurdles and accelerate clinical success.

Join C-suite executives, biotech leaders, and pharma experts as they shape the future of T-cell engagers. With increasing momentum and investment, now is the time to stay ahead of the latest breakthroughs driving the next wave of immune therapy innovation.

URLs:

Tickets: https://go.evvnt.com/2958550-2?pid=10008

Brochure: https://go.evvnt.com/2958550-3?pid=10008

Time: 8:30 AM - 4:20 PM

Prices:

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + 2 Workshops - Drug Developer Pricing: USD 4197.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference + 2 Workshops - Academic Pricing: USD 3597.00,

Conference Only - Solution Provider Pricing: USD 3699.00,

Conference + 2 Workshops - Solution Provider Pricing: USD 5097.00

Speakers: Joonhee Park, Senior Scientist, Amgen, Saso Cemerski, Executive Director, Immune Engagers, AstraZeneca, Flavio Lima Bianchi, Lead Research Analyst, Beacon, Simon Plyte, Chief Scientific Officer, Biomunex, Alexander Martinko, Director, Antibody Engineering and Design, Cartography Bio, Anthony Stein, Associate Director, Gehr Family Center for Leukemia Research City of Hope, Lauren Harshman, Senior Vice President, Clinical Development, Clasp Therapeutics, Kris Sachsenmeier, Vice President, Translational Sciences, Compass Therapeutics, Jeff Jones, Chief Medical Officer, Cullinan Therapeutics, Alfred Lim, Director, Biology, Etcembly, Chengbin Wu, Chief Executive Officer, EpimAb, Oksana Sergeeva, Principal Scientist, Translational Sciences, Evolveimmune, Chi-Chung Li, Senior Director, Distinguished Scientist, Clinical Pharmacology, Genentech, Krithika Mohan, Associate Director, GlaxoSmithKline, Kris Clark, Head, Biology, Greywolf Therapeutics, Samantha Bucktrout, Head, Research, Greywolf Therapeutics, Milos Aleksic, Senior Director, Drug Discovery, Immunocore, Dan Foxler, Head, Cell Biology, Assay Development, LabGenius Therapeutics, Huan Yang, Associate Principal Scientist, Merck, Giovanni Abbadessa, Chief Medical Officer, ModeX Therapeutics, David DiLillo, Senior Director, Regeneron, Starlynn Clarke, Director, Preclinical Biology, Rondo Therapeutics, Milton To, Senior Scientist, Vir Biotechnology, Nina Weisser, Senior Director, Multispecific Antibody Therapeutics, Zymeworks